Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
TMO$711.10+4.94(+0.70%)Thermo Fisher Scientific Introduces Value-Priced Thermo Scientific™ AmpSure™ Universal qPCR Master Mixes Without Compromising Performance8:30:16 AM ETTEAD$0.20-0.07(-25.93%)Ad platform Teads misses Q3 revenue estimates; suspends guidance8:29:01 AM ETC$126.60+1.83(+1.47%)UPDATE 6-Oil rises as investors weigh uncertainties around Iran war8:27:07 AM ETMRNA$255.60-2.74(-1.06%)Moderna, Humana and Elanco Earnings Previews: What Investors Should Watch8:18:32 AM ETAMD$463.56-25.22(-5.16%)AMD: The Bigger Earnings Opportunity Starts In 20278:17:47 AM ETV$439.98+3.39(+0.78%)Visa Just Raised Its Dividend 16%. Is It a Better Buy Than Mastercard?8:17:32 AM ETCVS$80.78+0.79(+0.99%)RPT-BREAKINGVIEWS-CVS’s problem: investors trust the warning label8:16:38 AM ETCOP$139.45+2.51(+1.83%)STAK Energy Signs Long-Term Agreement to Bring North Slope Natural Gas to Market8:15:00 AM ETMU$756.39-39.07(-4.91%)Is Micron stock a Buy after crashing below $800?8:13:57 AM ETGOOG$290.00+2.70(+0.94%)Meta Paid 1.4 Times What Alphabet Did to Borrow in Euros8:08:00 AM ETCOP$139.45+2.51(+1.83%)ConocoPhillips Profit Rises as Oil Prices Climb8:06:00 AM ETTCPC$4.35-0.03(-0.68%)BlackRock TCP Capital Corp. Announces Third Quarter 2026 Financial Results Including Net Investment Income of $0.16 Per Share; Declares a Fourth Quarter Dividend of $0.17 Per Share8:05:07 AM ETINTC$56.62-1.66(-2.85%)Intel: I Warned Before The 40% Crash, Now I'm Bullish (Rating Upgrade)8:05:00 AM ETASML$1,455.55-40.59(-2.71%)Could $10,000 Invested in ASML Set You Up for Life?8:05:00 AM ETAVGO$316.85-8.85(-2.72%)Broadcom Stock Could Be Approaching a Major Turning Point. Here's the Price Target8:03:07 AM ETVZ$46.51+0.34(+0.74%)Verizon Makes the Holidays Simple with Our Best Deals and Rewards Just for Being a Customer8:01:25 AM ETSHEL$102.80+0.94(+0.92%)Transaction in Own Shares8:00:53 AM ETIBM$256.40+2.08(+0.82%)IBM, AMD, Oak Ridge National Laboratory launch quantum error correction platform8:00:48 AM ETMETA$634.70+4.70(+0.75%)Voters rejected AI data centers over resource concerns. Here's why measuring water usage is hard8:00:01 AM ETISRG$484.18+1.99(+0.41%)World’s First Fully Robotic Transoral Gastric Procedures Completed Using EndoQuest’s Endoluminal Surgical System8:00:00 AM ETGOOG$290.00+2.70(+0.94%)Alphabet: Search Disruption Vs. The Rise Of Carbon8:00:00 AM ETAAPL$355.00+5.49(+1.57%)The new moto buds ultra 27 take audio up a notch with Sound by Bose technology and bring AI live translation to consumers8:00:00 AM ETTM$215.60+16.14(+8.09%)2027 Toyota Tundra: A Bold New Chapter in Full-Size Pickup Excellence with Advanced Towing Tech and the New Trailhunter Package8:00:00 AM ETIBM$256.40+2.08(+0.82%)Oak Ridge National Laboratory, IBM, and AMD Launch New Co-Design Platform for Quantum Error Correction8:00:00 AM ET

ANVS · NYSE

Annovis Bio, Inc.

$0.91 -0.29 (-23.85%)

Company overview

Annovis Bio, Inc., a clinical-stage drug platform company, develops drugs to treat neurodegeneration. Its lead compound is Buntanetap, an orally administered drug that has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, and is also in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. The company is also developing ANVS405 for protecting against traumatic brain injury and stroke, and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. Annovis Bio was incorporated in 2008 and is based in Berwyn, Pennsylvania.

Sector
Healthcare
Industry
Biotechnology
Exchange
NYSE
Market cap
$38.8M
Employees
8
Headquarters
Malvern, PA
Website
annovisbio.com
CEO
Maria L. Maccecchini
Listed
January 29, 2020
P/E
-0.53
Dividend yield
0.00%

Company financials

Revenue
$0.00
Gross profit
$0.00
Operating income
-$41.4M
EBITDA
-$41.4M
Net income
-$40.9M
EPS
-$1.72
Total assets
$16.2M
Total debt
$0.00
Earnings yield
-189.01%

Price chart

0.871.281.702.122.53
ANVS 1D NYSE O1.12H1.25L1.10C1.20+0.10 (+9.63%)Vol1.04M

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
ANVSAnnovis Bio, Inc. Press release Annovis Announces Pricing of $21.0 Million Public Offering GlobeNewswire
ANVSAnnovis Bio, Inc. Press release Annovis Announces Launch of Proposed Public Offering GlobeNewswire
ANVSAnnovis Bio, Inc. Stock news BRIEF-Annovis Bio, Receives Continued Listing Standard Notice From The NYSE Reuters
ANVSAnnovis Bio, Inc. Press release Annovis Bio, Inc. Receives Continued Listing Standard Notice from the NYSE GlobeNewswire
ANVSAnnovis Bio, Inc. Press release Annovis to Participate in U.S. Biotech Day 2026 and Pharma Partnering Summit 2026 GlobeNewswire
ANVSAnnovis Bio, Inc. Press release Annovis to Attend the CTAD 2026 with Three Presentations GlobeNewswire
ANVSAnnovis Bio, Inc. Press release Annovis Announces Partnership with Weave Bio, AI Regulatory Platform, in Preparation of NDA for Buntanetap in Alzheimer's Disease GlobeNewswire
ANVSAnnovis Bio, Inc. Stock news Annovis Bio (ANVS) Loses 26.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner Zacks Investment Research
ANVSAnnovis Bio, Inc. Stock news Annovis Bio Targets March 2027 Alzheimer's Readout, Prepares Rolling NDA MarketBeat
ANVSAnnovis Bio, Inc. Press release Annovis to Host Corporate Update Webinar on September 2, 2026 GlobeNewswire
ANVSAnnovis Bio, Inc. Press release Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results GlobeNewswire
ANVSAnnovis Bio, Inc. Press release Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer's Disease GlobeNewswire
ANVSAnnovis Bio, Inc. Press release Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer GlobeNewswire
ANVSAnnovis Bio, Inc. Press release Annovis Bio Regains NYSE Listing Compliance GlobeNewswire
ANVSAnnovis Bio, Inc. Press release Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants GlobeNewswire
ANVSAnnovis Bio, Inc. Press release Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants GlobeNewswire
ANVSAnnovis Bio, Inc. Press release Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results GlobeNewswire
ANVSAnnovis Bio, Inc. Press release Annovis CEO to Present on Multi-Protein Model of Alzheimer's Disease at Fierce Biotech Week 2026 GlobeNewswire
ANVSAnnovis Bio, Inc. Press release Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio GlobeNewswire
ANVSAnnovis Bio, Inc. Press release Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission GlobeNewswire
See more
FAQ

Questions about Annovis Bio, Inc.

What does Annovis Bio, Inc. do?
Annovis Bio, Inc., a clinical-stage drug platform company, develops drugs to treat neurodegeneration. Its lead compound is Buntanetap, an orally administered drug that has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, and is also in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. The company is also developing ANVS405 for protecting against traumatic brain injury and stroke, and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. Annovis Bio was incorporated in 2008 and is based in Berwyn, Pennsylvania.
What is ANVS's market cap?
Annovis Bio, Inc. (ANVS) is a listed stock with a live quote. The latest market cap on this page is $38.8M.
Where is Annovis Bio, Inc. headquartered?
Annovis Bio, Inc. is headquartered in Malvern, PA.
How do I get ANVS news from the API?
Call GET /v1/news?tickers=ANVS. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does ANVS news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for ANVS, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the ANVS price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs